Bank Of America Corp Rigel Pharmaceuticals Inc Transaction History

Bank Of America Corp

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$1.12 - $1.57 $65,428 - $91,716	-58,418 Reduced 34.27%	112,037 $165,000
Q4 2023 Feb 14, 2024	BUY	$0.72 - $1.56 $54,404 - $117,876	75,562 Added 79.63%	170,455 $247,000
Q2 2023 Aug 14, 2023	SELL	$1.12 - $1.82 $79,236 - $128,759	-70,747 Reduced 42.71%	94,893 $122,000
Q1 2023 May 12, 2023	SELL	$1.25 - $2.0 $24,001 - $38,402	-19,201 Reduced 10.39%	165,640 $218,000
Q4 2022 Feb 10, 2023	SELL	$0.67 - $11.9 $78,712 - $1.4 Million	-117,482 Reduced 38.86%	184,841 $277,000
Q3 2022 Nov 14, 2022	SELL	$1.1 - $12.2 $903,071 - $10 Million	-820,974 Reduced 73.09%	302,323 $356,000
Q2 2022 Aug 12, 2022	BUY	$0.67 - $3.19 $568,280 - $2.71 Million	848,180 Added 308.3%	1,123,297 $1.27 Million
Q1 2022 May 16, 2022	BUY	$2.22 - $3.45 $55,784 - $86,691	25,128 Added 10.05%	275,117 $822,000
Q4 2021 Feb 08, 2022	SELL	$2.36 - $3.57 $118,384 - $179,081	-50,163 Reduced 16.71%	249,989 $663,000
Q3 2021 Nov 15, 2021	BUY	$3.5 - $4.5 $11,077 - $14,242	3,165 Added 1.07%	300,152 $1.09 Million
Q2 2021 Sep 13, 2021	BUY	$3.09 - $4.54 $917,689 - $1.35 Million	296,987 New	296,987 $1.29 Million

334K

Ticker RIGL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 172,836,000
Market Cap $2.84B
Description
Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is ...

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

Stay updated on Bank Of America Corp with notifications on news.